NJF Capital

Tracked participation in 2 Atlas companies, with 0 explicitly attributed leads.

2portfolio companies

4round participations

0lead positions

nulllatest activity

Capital activity

Portfolio

CompanyLatest valuationFirst → latestRoundsRoleAttributed partner

OOwkinScienceOwkin is a privately held AI company building “agentic” biological AI products for drug discovery, clinical…$1Bvaluation$635.2MraisedRecent roundsTotal disclosed (company press kit aggregate) · null$304.1M · Bpifrance Large Ventures, Bristol-Myers Squibb +10Spin-out financing: Waiv (formerly Owkin Dx) · Mar 2026$33M · led by Alpha Intelligence Capital, OTB VenturesStrategic collaboration with Bristol Myers Squibb (incl. Series B-1 equity investment) · Jun 2022$80M · led by Bristol Myers SquibbOwkin—Jan 2018 → null3 roundsParticipant—

BBioptimus—Feb 2024 → Feb 20241 roundParticipant—

DateCompanyRoundRaisedValuationRoleEvidence

nullOOwkinScienceOwkin is a privately held AI company building “agentic” biological AI products for drug discovery, clinical…$1Bvaluation$635.2MraisedRecent roundsTotal disclosed (company press kit aggregate) · null$304.1M · Bpifrance Large Ventures, Bristol-Myers Squibb +10Spin-out financing: Waiv (formerly Owkin Dx) · Mar 2026$33M · led by Alpha Intelligence Capital, OTB VenturesStrategic collaboration with Bristol Myers Squibb (incl. Series B-1 equity investment) · Jun 2022$80M · led by Bristol Myers SquibbOwkinTotal disclosed (company press kit aggregate)$304.1M—Participant

Source ↗

Feb 20, 2024BBioptimusSeed$35M—Participant

Source ↗

Mar 07, 2019OOwkinScienceOwkin is a privately held AI company building “agentic” biological AI products for drug discovery, clinical…$1Bvaluation$635.2MraisedRecent roundsTotal disclosed (company press kit aggregate) · null$304.1M · Bpifrance Large Ventures, Bristol-Myers Squibb +10Spin-out financing: Waiv (formerly Owkin Dx) · Mar 2026$33M · led by Alpha Intelligence Capital, OTB VenturesStrategic collaboration with Bristol Myers Squibb (incl. Series B-1 equity investment) · Jun 2022$80M · led by Bristol Myers SquibbOwkinSeries A (venture round / extension)——Participant

Source ↗

Jan 16, 2018OOwkinScienceOwkin is a privately held AI company building “agentic” biological AI products for drug discovery, clinical…$1Bvaluation$635.2MraisedRecent roundsTotal disclosed (company press kit aggregate) · null$304.1M · Bpifrance Large Ventures, Bristol-Myers Squibb +10Spin-out financing: Waiv (formerly Owkin Dx) · Mar 2026$33M · led by Alpha Intelligence Capital, OTB VenturesStrategic collaboration with Bristol Myers Squibb (incl. Series B-1 equity investment) · Jun 2022$80M · led by Bristol Myers SquibbOwkinSeries A$11M—Participant

Source ↗

DateCompanyRoundRaisedValuationRoleEvidence

Source ↗

Feb 20, 2024BBioptimusSeed$35M—Participant

Source ↗